T1	p 43 66	myocardial infarction ]
T2	p 117 138	myocardial infarction
T3	p 227 251	patients on thrombolytic
T4	p 291 328	106 males with Q-MI entered the study
T5	p 378 398	30 patients received
T6	p 437 448	29 patients
T7	p 1038 1046	patients
T8	p 1090 1126	ventricular systolic dysfunction and
T9	i 6 39	[ Neoton and thrombolytic therapy
T10	i 85 99	neoton therapy
T11	i 144 145	)
T12	i 239 267	thrombolytic therapy ( TLT )
T13	i 343 375	treatment without TLT and neoton
T14	i 399 436	TLT with streptokinase preparations ,
T15	i 460 499	streptokinase preparations and neoton .
T16	i 551 567	echocardiography
T17	i 638 648	monitoring
T18	i 667 669	MI
T19	i 791 797	neoton
T20	i 976 982	neoton
T21	i 1019 1025	Neoton
T22	i 1057 1060	TLT
T23	o 117 127	myocardial
T24	o 149 166	systolic function
T25	o 174 223	left ventricle , arrhythmia and clinical symptoms
T26	o 498 534	. Left ventricular systolic function
T27	o 602 614	; arrhythmia
T28	o 694 741	arrest progression of left ventricular dilation
T29	o 760 773	hospital stay
T30	o 843 877	end systolic and diastolic volumes
T31	o 881 884	the
T32	o 949 972	. Antiarrhythmic action
T33	o 1070 1110	progression of left ventricular systolic